🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

22 results for “Oric” Clear

  1. Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix

    Lacuna Pharma Pty Ltd

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial

  2. Placebo, DRY EXTRACT FROM CHASTE TREE FRUITS (7-11:1), EXTRACTION SOLVENT: ETHANOL 70% (V/V)

    Topiloric/Uriadec

    Primary Dysmenorrhea

    phase 3 small molecule active

    1 trial

  3. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  4. VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  5. Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid), Ruxolitinib (INCB018424) cream

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  6. Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  7. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  8. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  9. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  10. Powder for concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets, Zyloric 300 mg Tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Zyloric 100 mg Tablet

    The George Institute

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    phase 2 small molecule active

    1 trial

  11. ORIC-101

    Topiloric/Uriadec

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  12. ORIC-101

    Topiloric/Uriadec

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  13. ORIC-101

    Topiloric/Uriadec

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  14. ORIC-114

    Topiloric/Uriadec

    Food Effect in Healthy Participants

    phase 1 small molecule completed

    1 trial

  15. ORIC-114 Dose 1 + amivantamab

    Topiloric/Uriadec

    Solid Tumors

    phase 1 small molecule active

    1 trial

  16. ORIC-533

    Topiloric/Uriadec

    Relapsed or Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  17. ORIC-944

    Topiloric/Uriadec

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  18. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  19. Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD

    Topiloric/Uriadec

    chronic liver disease

    phase 1 other active

    1 trial

  20. Voriconazole 200mg

    The First People's Hospital of Lianyungang

    Cryptococcal Meningitis

    phase 1 small molecule active

    1 trial

  21. Sesame Oil

    United Therapeutics Europe Ltd

    Caloric Restriction

    approved small molecule completed

    1 trial

  22. high caloric oral nutritional supplements

    The First People's Hospital of Lianyungang

    Malnutrition, Child

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources